|
**Overview**: JAK2 CALR MPL Panel**Introduction**: The JAK2 CALR MPL Panel is a diagnostic tool designed for comprehensive MPN mutation screening using whole blood samples. In India, driver mutations (JAK2 V617F ~50-95 percent, CALR ~20-25 percent in ET/PMF, MPL ~5-10 percent) define WHO classification of myeloproliferative neoplasms, with triple-negative cases rarer but aggressive. High morbidity from under-testing in rural/low-SES patients with unexplained erythrocytosis/thrombocytosis/splenomegaly, limited molecular labs, delayed targeted therapy (ruxolitinib) leading to thrombosis or myelofibrosis progression. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs PCR for JAK2 V617F, CALR, and MPL mutations over 1-2 days with high accuracy, valuable for driver mutation identification and risk stratification. This diagnostic falls under genetic cancer screening and targets patients with suspected MPN or unexplained cytoses, addressing accurate detection to guide cytoreduction, JAK inhibitors, or monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular classification and reducing MPN complications. Its whole blood-based approach ensures reliable multi-gene analysis.**Other Names**: JAK2 CALR MPL Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: CALR/MPL discovery 2013; in India, triple-driver panel routine in MPN.**Purpose**: The test assesses 3 parameters including JAK2 V617F mutation to guide comprehensive MPN screening, identify driver mutations, inform therapy.**Test Parameters**: 1. JAK2 V617F Mutation, 2. CALR Mutation, 3. MPL Mutation.**Pretest Condition**: No fasting required; patients should report cytosis or splenomegaly.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on blood counts, thrombosis, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed MPN including thrombosis, benefits of mutation profiling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive driver mutation confirms MPN diagnosis, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Bone marrow biopsy, NGS for triple-negative cases.**Test Limitations**: Detects common drivers; comprehensive approach required.**References**: Indian Journal of Hematology 2024, MPN Studies India 2023. |
